Heron Therapeutics, Inc. (NASDAQ:HRTX – Get Free Report) CFO Ira Duarte acquired 85,000 shares of the stock in a transaction dated Thursday, November 16th. The shares were bought at an average cost of $0.89 per share, with a total value of $75,650.00. Following the completion of the transaction, the chief financial officer now owns 85,000 shares of the company’s stock, valued at approximately $75,650. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Heron Therapeutics Price Performance
Shares of HRTX traded up $0.14 during mid-day trading on Friday, reaching $1.06. The company had a trading volume of 6,397,622 shares, compared to its average volume of 2,266,309. The company’s 50-day moving average is $0.87 and its 200-day moving average is $1.27. Heron Therapeutics, Inc. has a twelve month low of $0.50 and a twelve month high of $3.41. The company has a market capitalization of $158.85 million, a P/E ratio of -1.05 and a beta of 1.12.
Heron Therapeutics (NASDAQ:HRTX – Get Free Report) last announced its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.12). The firm had revenue of $31.76 million during the quarter, compared to the consensus estimate of $31.75 million. Heron Therapeutics had a negative net margin of 97.45% and a negative return on equity of 21,127.62%. As a group, equities analysts expect that Heron Therapeutics, Inc. will post -1.09 EPS for the current fiscal year.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
A number of analysts recently commented on HRTX shares. Needham & Company LLC decreased their price objective on Heron Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Wednesday. StockNews.com raised Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
- Five stocks we like better than Heron Therapeutics
- Insider Trades May Not Tell You What You Think
- 3 large caps with red hot RSIs with upside
- How to Invest in Solar Energy
- Johnson Controls International: Nothing but upside for investors
- How to Invest in Virtual Reality
- Unity Software’s resilient rebound post-earnings setback
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.